Gorin N C, Salmon C, Duhamel G
Ann Med Interne (Paris). 1986;137(2):92-9.
Autologous bone marrow transplantation (ABMT) is a new technique which is currently being evaluated in the treatment of leukemias, lymphomas, and a few solid tumors. In patients with acute leukemia (AL), high dose therapy + ABMT is of little benefit if done at time of relapse. On the other hand, when used for consolidation of remission, either with cleansed or non cleansed marrow, it may improve disease-free survival. In patients with acute myelocytic leukemia (AML) autografted during their 1st remission, the probability of remaining in remission at 2 years is 70 p. 100. It is slightly lower for patients with acute lymphocytic leukemia (ALL): 55 p. 100. The different techniques of cleansing the marrow, monoclonal antibodies, immunotoxins, drugs, are reviewed in this paper. A comparison of these techniques in term of tumor log cell kill is provided. ABMT is the best second line therapy for non-Hodgkin lymphomas (NHL), either after relapse after conventional chemotherapy or partial failure (partial remission). In these patients, the probability of remaining in remission at 3 years is about 50 p. 100. ABMT is currently under trial in the treatment of solid tumors and some success has been obtained in carcinoma of the ovary, non-seminomatous tumor of the testis, neuroblastoma, and some selected breast cancers.
自体骨髓移植（ABMT）是一种新技术，目前正在评估其在白血病、淋巴瘤和少数实体瘤治疗中的应用。对于急性白血病（AL）患者，在复发时进行高剂量治疗加ABMT益处不大。另一方面，当用于缓解期巩固时，无论是使用净化骨髓还是未净化骨髓，都可能提高无病生存率。在首次缓解期进行自体移植的急性髓细胞白血病（AML）患者中，两年内保持缓解的概率为70%。急性淋巴细胞白血病（ALL）患者的这一概率略低，为55%。本文综述了净化骨髓的不同技术，包括单克隆抗体、免疫毒素、药物等。并对这些技术在肿瘤对数细胞杀伤方面进行了比较。ABMT是治疗非霍奇金淋巴瘤（NHL）的最佳二线疗法，无论是在传统化疗后复发还是部分缓解（部分失败）之后。在这些患者中，三年内保持缓解的概率约为50%。ABMT目前正在用于实体瘤治疗的试验中，并且在卵巢癌、睾丸非精原细胞瘤、神经母细胞瘤和一些特定的乳腺癌治疗中已取得了一些成功。
